ERBB2 and breast carcinoma: Samples sub-classified as PI3K pathway active or inactive (classification was based on PIK3CA mutations and amplification, ERBB2 amplification or over-expression, or PTEN deletion or mutation) exhibited similar rates of these alterations, regardless of PIK3CA mutation status or breast cancer subtype.